Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer.

Amrane, Karim; Campedel, Luca; Le Meur, Coline; Abgral, Ronan; Kharroubi, Dris; Cadranel, Jacques

Amrane, Karim; Campedel, Luca; Le Meur, Coline; Abgral, Ronan; Kharroubi, Dris; Cadranel, Jacques.

Afiliação

Amrane K; Department of Oncology, Pitié Salpêtrière Hospital, Paris, France.
Campedel L; Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Le Meur C; Department of Oncology, Pitié Salpêtrière Hospital, Paris, France.
Abgral R; Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Kharroubi D; Department of Nuclear Medicine, University Hospital of Brest, Brest, France.
Cadranel J; Department of Nuclear Medicine, Pitié Salpêtrière Hospital, Paris, France.

Front Med (Lausanne) ; 8: 691253, 2021.

Article em En | MEDLINE | ID: mdl-34660618

Palavras-chave

ALK; FDG-PET/CT; NSCLC; ROS1; crizotinib; therapeutic assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google